Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA)

Journal of Neuro-Oncology

Volumn 87, Issue 2, 2008, Pages 133-141

  Spiller, Susan E ^a,b   Ditzler, Sally H ^a   Pullar, Barbara J ^a   Olson, James M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brain; Medulloblastoma; Pediatric; Retinoic acid; SAHA

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CISPLATIN; ISOTRETINOIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; INTRACRANIAL TUMOR; MEDULLOBLASTOMA; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CISPLATIN; HYDROXAMIC ACIDS; ISOTRETINOIN; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 41549151359     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9505-1     Document Type: Article

References (33)

1. McNeil DE, Cote TR, Clegg L, Rorke LB (2002) Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Med Pediatr Oncol 39:190-194
2. Gilbertson RJ (2004) Medulloblastoma: Signalling a change in treatment. Lancet Oncol 5:209-218
3. Geyer JR, Sposto R, Jennings M et al (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 23:7621-7631
4. Silber JH, Radcliffe J, Peckham V et al (1992) Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score. J Clin Oncol 10:1390-1396
5. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, Sainte-Rose C, Pierre-Kahn A, Hirsch JF (1990) Medulloblastoma in childhood: Progressive intellectual deterioration. Childs Nerv Syst 6:60-65
6. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM (2001) Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol 19:3470-3476
7. Copeland DR, deMoor C, Moore BD, Ater JL (1999) Neurocognitive development of children after a cerebellar tumor in infancy: A longitudinal study. J Clin Oncol 17:3476-3486
8. Xu W, Janss A, Packer RJ, Phillips P, Goldwein J, Moshang T (2004) Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro-Oncology 6:113-118
9. Ranke MB, Price DA, Lindberg A, Wilton P, Darendeliler F, Reiter EO (2005) Final height in children with medulloblastoma treated with growth hormone. Horm Res 64:28-34
10. Knight KRG, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596
11. Miller WH (1998) The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83:1471-1482
12. Hallahan AR, Pritchard JI, Chandraratna RA et al (2003) BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9:1033-1038
13. Spiller SE, Ravanpay AC, Hahn AW, Olson JM (2006) Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 79:259-270
14. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223-229
15. Sonnemann J, Kumar KS, Heesch S et al (2006) Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766
16. Hallahan AR, Pritchard JI, Hansen S et al (2004) The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64:7794-7800
17. Khan AA, Villablanca JG, Reynolds CP, Avramis VI (1996) Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 39:34-41
18. Freemantle SJ, Spinella MJ, Dmitrovsky E (2003) Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene 22:7305-7315
19. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278(14):12579-12589
20. Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101:18030-18035
21. Coffey DC, Kutko MC, Glick RD et al (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61:3591-3594
22. Wang X, Qian DZ, Ren M et al (2005) Epigenetic modulation of retinoic acid receptor β2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11:3535-3542
23. Touma SE, Goldberg JS, Moench P et al (2005) Retinoic acid and the histone deacetylase inhibitor trichostatin A inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 11:3558-3566
24. Ferrara FF, Fazi F, Bianchini A et al (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61:2-7
25. Demary K, Wond L, Spanjaard RA (2001) Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163:103-108
26. NCI website: http://www.cancer.gov/clinicaltrials. Accessed May 15, 2007
27. Packer RJ, Goldwin J, Nicholson HS et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group study. J Clin Oncol 17(7):2127-2136
28. Aebi S, Kroning R, Cenni B et al (1999) All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res 3:2033-2038
29. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300
30. Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H (2006) Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28:1233-1241
31. Pilatrino C, Cilloni D, Messa E et al (2005) Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 104:101-109
32. Kuendgen A, Strupp C, Alvado M et al (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269
33. Bug G, Ritter M, Wassmann B et al (2005) Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104:2717-2725